Fianlimab - Regeneron Pharmaceuticals
Alternative Names: Anti-LAG-3 antibody - Regeneron Pharmaceuticals; REGN-3767Latest Information Update: 29 Aug 2024
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Malignant melanoma
- Phase II/III Non-small cell lung cancer
- Phase II Solid tumours
- Phase I Haematological malignancies
Most Recent Events
- 26 Aug 2024 Columbia University plans a phase II trial for Bladder cancer (Combination therapy) in USA (IV) (NCT06571708)
- 21 Aug 2024 Phase I development is ongoing for Haematological malignancies (Late-stage disease, Combination therapy) in Australia, Ireland, South Korea, United Kingdom, USA (IV) (Regeneron pipeline, May 2024)
- 19 Aug 2024 Phase-III clinical trials in Malignant melanoma (Combination therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease, First-line therapy) in USA (IV) (NCT06246916)